Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient [1]

Therapeutic Drug Monitoring

Volumn 27, Issue 1, 2005, Pages 107-108

  Kunicki, Paweł K ^a   Sobieszczańska Máek, Małgorzata ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZATHIOPRINE; CLARITHROMYCIN; CREATININE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; OMEPRAZOLE; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; CASE REPORT; CLINICAL FEATURE; COMPETITIVE INHIBITION; CREATININE BLOOD LEVEL; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MONITORING; DUODENITIS; ERADICATION THERAPY; GASTROSCOPY; HEART TRANSPLANTATION; HELICOBACTER PYLORI; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; PRIORITY JOURNAL; TREATMENT WITHDRAWAL;

AREA UNDER CURVE; AZATHIOPRINE; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DUODENITIS; HALF-LIFE; HEART TRANSPLANTATION; HELICOBACTER INFECTIONS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; TACROLIMUS;

EID: 13244277434     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200502000-00020     Document Type: Letter

References (9)

1. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Safety. 1997;16:267-278.
2. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41:813-851.
3. Cervelli MJ, Russ GR. Itraconazole-tacrolimus drug interaction. Ther Drug Monit. 2003;25:483-484.
4. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther. 2001;69:158-168.
5. Ushiama H, Echizen H, Nachi S, et al. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearence to 6β-hydroxycortisol. Clin Pharmacol Ther. 2002;72:33-43.
6. Gomez G, Alvarez ML, Errasti P, et al. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. Transplant Proc. 1999;31:2250-2251.
7. Wolter K, Wagner K, Philipp T, et al. Interaction between FK 506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol. 1994;47:207-208.
8. Katari SR, Magnone M, Shapiro R, et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clin Transplant. 1997;11:237-242.
9. Ibrahim RB, Abella EM, Chandrasekar PH. Tacrolimus-clarithromycin interaction in a patient receiving bone marrow transplantation. Ann Pharmacother. 2002;36:1971-1972.